Novartis Ends BioArctic Brain-Drug Partnership
Adults following Alzheimer's research should note that BioArctic's brain-delivery technology continues in other partnerships.
Updated on Nov. 3, 2026 in Alzheimer’s
Novartis has discontinued its brain-penetrant therapy collaboration with Swedish biotech BioArctic, BioArctic announced on Monday. BioArctic said the decision was Novartis's own and unrelated to its BrainTransporter technology, which is designed to help therapeutic candidates cross the blood-brain barrier.
Why it matters
For people living with Alzheimer's and other neurodegenerative diseases, the blood-brain barrier is one of the biggest obstacles to effective treatment, so changes in which drug-delivery programs continue affect the pipeline of candidates that might eventually reach patients. The termination shows that even well-funded partnerships can be ended, and BioArctic's other collaborations are now the main indicators of where this technology is heading.
This is a corporate partnership announcement rather than a clinical study, so no trial size, efficacy result, or patient population is available. The reported figures are deal terms, including upfront payments and milestone eligibility, which indicate the financial scale of the collaborations rather than their scientific results.
The players
BioArctic
A Swedish biotechnology company focused on neurodegenerative diseases, known for its BrainTransporter technology and its work on Alzheimer's antibody therapies.
Novartis
A Swiss pharmaceutical company with a broad therapeutic portfolio that has partnered with BioArctic on brain-penetrant drug delivery.
Eli Lilly
A U.S. pharmaceutical company with a major Alzheimer's research program that is developing a neurodegenerative disease candidate with BioArctic.
Bristol Myers Squibb
A U.S. pharmaceutical company that licensed BioArctic's experimental pyroglutamate-amyloid-beta antibodies in 2024.
Eisai
A Japanese pharmaceutical company with a long-standing partnership with BioArctic, whose pact was extended shortly before the Bristol Myers Squibb deal.
The details
BioArctic's BrainTransporter platform is designed to attach therapeutic candidates to a carrier that can cross the blood-brain barrier, the protective layer that blocks many drugs from reaching brain tissue. Under the Novartis arrangement, Novartis paid $30 million upfront so BioArctic could generate a candidate by combining this platform with an undisclosed antibody supplied by Novartis. The termination ends that specific program, while BioArctic's separate work with Eli Lilly on a neurodegenerative candidate continues using the same technology.
Timeline
The Novartis collaboration began about one year before its termination.
BioArctic licensed its experimental antibodies to Bristol Myers Squibb in 2024.
BioArctic announced the Novartis termination on Monday, November 2, 2026.
Health Landscape
Delivering drugs across the blood-brain barrier remains a central challenge in Alzheimer's and other neurodegenerative disease research. BioArctic's ongoing partnerships with Eisai, Bristol Myers Squibb, and Eli Lilly show that the field is still investing in this approach even as individual collaborations end.
If you or a family member are following Alzheimer's treatment developments, it is worth asking your doctor which clinical trials are currently enrolling and how new drug-delivery approaches might relate to available options. Partnership changes like this one do not alter current care, and any decisions about treatment should be made in consultation with a physician.
The takeaway
Delivering treatments across the blood-brain barrier is one of the field's hardest problems, and partnerships are a key way it advances. Readers interested in Alzheimer's research can ask their physician about clinical trial options and follow updates from the companies developing these candidates.
Further reading
For background on the disease these brain-delivery therapies target, explore our coverage in Alzheimer's.
